Decreased PTPN12 expression associated with poor prognosis in HCC
As reported in PLoS ONE, the expression of PTPN12 was decreased in hepatocellular carcinoma tissue samples compared with adjacent normal tissues. Furthermore, decreased PTPN12 expression was associated with tumor recurrence, decreased cancer-specific survival, and decreased recurrence-free survival.
SIRT3 expression improves prognosis in gastric cancer
As reported in the World Journal of Surgery, SIRT3 expression improves the prognosis in patients with gastric cancer (n=221). Specifically, the 5-year OS was 51.2% and 39.1% in patients who do and do not express SIRT3, respectively. The 5-year DFS was 49.6% and 38.0% in patients who do and do not express SIRT3, respectively. Patients who do not express SIRT3 are characterized by increased poor cellular differentiation, increased diffuse-type Lauren’s histology, and increases scirrhous-type stromal reactions, suggesting the SIRT3 functions as a tumor suppressor.
SCCA-IgM predicts survival in HCC patients
As reported in the Journal of Gastroenterology & Hepatology, SCCA-IgM levels are elevated in patients with hepatocellular carcinoma (HCC) compared to patients with cirrhosis and healthy controls. Not only does the SCCA-IgM level predict overall and progression-free survival in HCC patients, but the sensitivity of SCCA-IgM in patients with HCC was 2-fold greater than AFP. A decline in SCCA-IgM levels was shown to be associated with response to treatment.